Fecal Microbiota Transplantation for Ulcerative Colitis

(FRONTIER-UC Trial)

This trial tests whether fecal microbiota transplantation (FMT) can help people with ulcerative colitis (UC), a condition that inflames the colon, causing pain and digestive problems. Participants will take capsules containing either the active treatment (lyophilized fecal microbiota transplantation) or a placebo (a look-alike pill with no active ingredient) to determine FMT's effectiveness and safety. This first-phase study aims to assess the feasibility of a larger trial. Individuals with an active diagnosis of ulcerative colitis, who can manage daily symptoms, and are willing to follow study guidelines might be suitable candidates. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications, but you must stop using non-dietary probiotics and antibiotics before joining. It's best to discuss your specific medications with the trial team.

Earlier research has shown that fecal microbiota transplantation (FMT) holds potential for treating ulcerative colitis. One study found that about 50% of patients who received FMT went into remission, compared to about 29% in the group that did not receive FMT, suggesting FMT's effectiveness.

Regarding safety, some studies have reported side effects. For instance, during an 8-week period, 67% of patients who received FMT experienced side effects. Interestingly, 85% of patients in the placebo group also reported side effects, indicating that side effects are common but not necessarily more frequent than those from a placebo.

Researchers are excited about lyophilized fecal microbiota transplantation (LFMT) for ulcerative colitis because it introduces a novel approach by using beneficial bacteria from healthy donors to restore gut balance. Unlike conventional treatments such as anti-inflammatory drugs, immunosuppressants, or biologics, LFMT directly targets the gut microbiome, potentially addressing the root cause of inflammation rather than just the symptoms. Additionally, this treatment is administered in capsule form, making it a non-invasive and potentially more convenient option compared to traditional therapies. This method offers the promise of a more natural and holistic approach to managing ulcerative colitis symptoms.

Research has shown that fecal microbiota transplantation (FMT) can help treat ulcerative colitis. In one study, about 50% of patients who received FMT experienced significant symptom improvement. Another study found that FMT, when combined with antibiotics, also led to symptom relief. A review of several studies found that 62% of people receiving FMT improved, compared to 50.5% of those who did not receive it. This trial will evaluate the effectiveness of Lyophilized Fecal Microbiota Transplantation (LFMT) in different treatment arms. These findings suggest that FMT might help people with ulcerative colitis feel better by altering the balance of bacteria in their gut.²³⁴⁶⁷